Plasma Cathepsin L: a Prognostic Marker for Pancreatic Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Dec 18

PMID 25516668

Citations 14

Authors

Nidhi Singh

Prasenjit Das

Surabhi Gupta

Vikas Sachdev

Siddhartha Srivasatava

Siddhartha Datta Gupta

Ravindra Mohan Pandey

Peush Sahni

Shyam S Chauhan

Anoop Saraya

Affiliations

Soon will be listed here.

Abstract

Aim: To assess the prognostic significance of cathepsin L, a cysteine protease that degrades the peri-tumoral tissue, in patients with pancreatic cancer.

Methods: Plasma samples from 127 pancreatic cancer patients were analyzed for cathepsin L levels by ELISA. Out of these patients, 25 underwent surgery and their paraffin-embedded tissue was analyzed for cathepsin L expression by immunohistochemistry. Survival of patients and clinicopathological parameters was correlated with cathepsin L expression in plasma and tissue using appropriate statistical analysis.

Results: The mean (± SD) cathepsin L in plasma samples of pancreatic cancer patients was 5.98 ± 2.5 ng/mL that was significantly higher compared to the levels in healthy controls (3.83 ± 0.45) or chronic pancreatitis patients (3.97 ± 1.06). Using ROC curve, a cut-off level of 5.0 ng/mL was decided for survival analysis. Elevated plasma levels of cathepsin L were found to be associated with poor prognosis (P = 0.01) in multivariate analysis. The plasma levels of the protease decreased after surgery. Though no significant correlation was seen between plasma and tissue expression of this protease, a trend did emerge that high cathepsin L expression in tissue correlated with its high levels in plasma.

Conclusion: Cathepsin L levels in plasma of pancreatic cancer patients may be used as a potential prognostic marker for the disease.

Citing Articles

Non-Canonical, Extralysosomal Activities of Lysosomal Peptidases in Physiological and Pathological Conditions: New Clinical Opportunities for Cancer Therapy.

Conesa-Bakkali R, Morillo-Huesca M, Martinez-Fabregas J Cells. 2025; 14(2).

PMID: 39851495 PMC: 11763575. DOI: 10.3390/cells14020068.

Cathepsin L in Lung Adenocarcinoma: Prognostic Significance and Immunotherapy Response Through a Multi Omics Perspective.

Lu J, Liang J, Xiao G, He Z, Yu G, Zhang L Cancer Inform. 2024; 23:11769351241307492.

PMID: 39687501 PMC: 11648051. DOI: 10.1177/11769351241307492.

Exocrine-Endocrine Crosstalk: The Influence of Pancreatic Cellular Communications on Organ Growth, Function and Disease.

Overton D, Mastracci T Front Endocrinol (Lausanne). 2022; 13:904004.

PMID: 35769082 PMC: 9234176. DOI: 10.3389/fendo.2022.904004.

Apoferritin encapsulation of cysteine protease inhibitors for cathepsin L inhibition in cancer cells.

Quilles Junior J, Carlos F, Montanari A, Leitao A, Mignone V, Arruda M RSC Adv. 2022; 9(63):36699-36706.

PMID: 35539052 PMC: 9075514. DOI: 10.1039/c9ra07161j.

Characterization and molecular docking study of cathepsin L inhibitory peptides (SnuCalCpIs) from Calotropis procera R. Br.

Kwon C, Yeo S, Chang P Sci Rep. 2022; 12(1):5825.

PMID: 35388095 PMC: 8986768. DOI: 10.1038/s41598-022-09854-x.

References

Chen Q, Fei J, Wu L, Jiang Z, Wu Y, Zheng Y . Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. Oncol Lett. 2012; 2(4):693-699. PMC: 3406412. DOI: 10.3892/ol.2011.302. View

Lah T, Strukelj B, Pungercar J, Barlic-Maganja D, Drobnic-Kosorok M, Kastelic L . Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer. 1992; 50(1):36-44. DOI: 10.1002/ijc.2910500109. View

Lankelma J, Voorend D, Barwari T, Koetsveld J, Van Der Spek A, De Porto A . Cathepsin L, target in cancer treatment?. Life Sci. 2009; 86(7-8):225-33. DOI: 10.1016/j.lfs.2009.11.016. View

Wray C, Ahmad S, Matthews J, Lowy A . Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005; 128(6):1626-41. DOI: 10.1053/j.gastro.2005.03.035. View

Mohamed M, Sloane B . Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006; 6(10):764-75. DOI: 10.1038/nrc1949. View

Leto G, Tumminello F, Pizzolanti G, Montalto G, Soresi M, Gebbia N . Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncology. 1997; 54(1):79-83. DOI: 10.1159/000227666. View

Nishida Y, Kohno K, Kawamata T, Morimitsu K, Kuwano M, Miyakawa I . Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol Oncol. 1995; 56(3):357-61. DOI: 10.1006/gyno.1995.1063. View

Collette J, Bocock J, Ahn K, Chapman R, Godbold G, Yeyeodu S . Biosynthesis and alternate targeting of the lysosomal cysteine protease cathepsin L. Int Rev Cytol. 2004; 241:1-51. DOI: 10.1016/S0074-7696(04)41001-8. View

Liotta L . Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986; 46(1):1-7. View

10.

Sivaparvathi M, Yamamoto M, Nicolson G, Gokaslan Z, Fuller G, Liotta L . Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metastasis. 1996; 14(1):27-34. DOI: 10.1007/BF00157683. View

11.

Yeo C, Cameron J, Lillemoe K, Sitzmann J, Hruban R, Goodman S . Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995; 221(6):721-31; discussion 731-3. PMC: 1234702. DOI: 10.1097/00000658-199506000-00011. View

12.

Niedergethmann M, Wostbrock B, Sturm J, Willeke F, Post S, Hildenbrand R . Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas. 2004; 29(3):204-11. DOI: 10.1097/00006676-200410000-00005. View

13.

Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M . Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 1991; 266(8):5147-52. View

14.

Sloane B . Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol. 1990; 1(2):137-52. View

15.

Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar L, Hritz I . Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer. 2008; 8:194. PMC: 2474636. DOI: 10.1186/1471-2407-8-194. View

16.

Yan J, Xiao H, Ji H, Shen W, Zhou Z, Song B . Cathepsin L is associated with proliferation and clinical outcome of urothelial carcinoma of the bladder. J Int Med Res. 2011; 38(6):1913-22. DOI: 10.1177/147323001003800604. View

17.

Leto G, Tumminello F, Pizzolanti G, Montalto G, Soresi M, Carroccio A . Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas. 1997; 14(1):22-7. DOI: 10.1097/00006676-199701000-00004. View

18.

Xu X, Yuan G, Liu W, Zhang Y, Chen W . Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance. Exp Oncol. 2009; 31(2):102-5. View

19.

Nomura T, Katunuma N . Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest. 2005; 52(1-2):1-9. DOI: 10.2152/jmi.52.1. View

20.

Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50(3):163-70. View